Stay updated with breaking news from Daniel Javitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that...
Item 1.01. Entry into a Material Definitive Agreement. On June 6, 2023, the Company entered into a securities purchase agreement with the purchasers signatory... | June 7, 2023
/PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the publication of all data (https://doi.org/10.1016/j.schres.2023.02.018) from a...
American-Israeli company NRx is currently undergoing a trial that combines two kinds of compounds hoping to reduce the negative side effects of current medicine
The Israeli company, which is developing drugs for the treatment of Covid respiratory failure and suicidal bipolar depression, has begun trading on Nasdaq as NrX Pharmaceuticals.